(PharmaNewsWire.Com, January 17, 2018 ) The global depression screening/mental health market has been evaluated as a moderately growing market and it is expected to continue growing in the near future. Increasing cases of patients with various mental disorders, rising investments in R&D, changing and stressful lifestyle are driving the growth for the market.
The market for depression screening/mental health was around USD 8263.6 million in 2016 and is expected to reach USD 11245.6 million which is projected to grow at a CAGR of 4.5% by 2023.
Major players in Depression Screening/Mental Health market:
There are plenty of large and small market players which operate in this market: Alkermes (Republic of Ireland), ALLERGAN (Republic of Ireland), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (US), Novartis AG (Switzerland), Otsuka Holdings Co.,Ltd. (Japan), Pfizer Inc. (US), and others.
Major players of this industry are funding R&D to derive effective solutions for mental health. Major players of this market are holding majority of market share while due to high investment cost, medium and small companies mainly focusing only on manufacturing of drugs rather than R&D.
In 2015, U S Food and Drug Administration (FDA) approved three major drugs which can be useful for the treatment of schizophrenia and other mental disorders. These drugs are Alkermes’s Aristada (aripiprazole lauroxil) extended-release injectable, Otsuka Holdings Co.,Ltd.’s Rexulti (brexpiprazole), and ALLERGAN’s Vraylar (cariprazine).
Pacifica Labs, Inc. is mobile healthcare solutions provider has developed an app which can detect stress and anxiety. This app is very helpful in management of stress and anxiety.
Regional Analysis:
Considering the global scenario of the Depression Screening/Mental Health market, the Americas are holding the largest market share in global depression screening/mental health in 2016. America is top revenue generator in global market that is mainly due to some factors like increasing funding for research and clinical trials. European market is the second largest market for depression screening/mental health. Increasing prevalence and growing knowledge of mental disorders are key drivers for the growth of Asia Pacific Depression Screening/Mental Health market. Middle East and Africa depression screening/mental health market is expected to limited growth it is mostly because of limited lack of knowledge of disorders and treatments, access to the healthcare, traditional healthcare practices etc.
Segmentation:
Global Depression Screening/Mental Health market has been segmented on the basis of disorder which comprise anxiety, mood disorders, depression, bipolar, psychotic, eating disorders, impulse control and addiction disorders, personality disorders, stress response syndromes, dissociative disorder, somatic symptom disorder, factitious disorder, and others. Anxiety is further sub-segmented into Generalized Anxiety Disorder (GAD), panic disorder, phobias, social phobia, agoraphobia, Obsessive-Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD). Mood disorder is further sub-segmented into dysthymia, substance-induced mood disorder, major depression, and others. Depression is further sub-segmented into atypical depression, chronic depression, melancholic depression, catatonic depression, Seasonal affective disorder (SAD), and others. Bipolar disorder is further sub-segmented into bipolar I disorder, bipolar II disorder, cyclothymic disorder, and others. Psychotic disorder is further sub-segmented into schizophrenia, delusional disorder, and others. Eating disorder is further sub-segmented into anorexia nervosa, binge eating disorder, bulimia nervosa, and others. Impulse control and addiction disorder is further sub-segmented into intermittent explosive disorder, pyromania, kleptomania, and others. Personality disorders includes emotional and impulsive, suspicious, anxious, and others. Dissociative disorder sub-segmented into dissociative amnesia, dissociative identity disorder, depersonalization-derealization disorder, and others. Somatic symptom disorder somatization disorder, conversion disorder, hypochondriasis, factitious disorder, body dysmorphic disorder, and others. Factitious disorder is further sub-segmented into factitious disorder with mostly psychological symptoms, factitious disorder with mostly physical symptoms, factitious disorder with both psychological and physical symptoms, and others.
On the basis of diagnosis, the market has been segmented into psychological test, Lab tests, Depression Screening Tests and others. Psychological test is further sub-segmented into intelligence tests, attitude tests, personality tests, achievement tests, and others. Lab tests sub-segmented into blood tests, CT scan or MRI of the brain, Electroencephalogram (EEG), Electrocardiogram (ECG). Depression Screening Tests includes Patient Health Questionnaire-10 (PHQ-10), Beck Depression Inventory (BDI), Zung Self-Rating Depression Scale, Center for Epidemiologic Studies-Depression Scale (CES-D), Hamilton Rating Scale for Depression (HRSD).
On the basis of treatment, the market has been segmented into medication, psychotherapy, brain-stimulation treatments, hospitalization, substance abuse treatment, and others. Medication includes anti-anxiety medications, antidepressants, antipsychotic medications, mood-stabilizing medications, opioid antagonists, atypical neuroleptics, glutamatergic agents, and others. Psychotherapy is further sub-segmented into cognitive and behavioral therapies, humanistic therapies, psychoanalytical and psychodynamic therapies, and others. Brain-stimulation treatments includes repetitive Transcranial Magnetic Stimulation (rTMS), Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), and others.
On the basis of end user, it is segmented into hospitals & clinics, medical research centers, academic institutes, and others.
Bipolar disorder is further sub-segmented into bipolar I disorder, bipolar II disorder, cyclothymic disorder, and others. Psychotic disorder is further sub-segmented into schizophrenia, delusional disorder, and others. Eating disorder is further sub-segmented into anorexia nervosa, binge eating disorder, bulimia nervosa, and others. Impulse control and addiction disorder is further sub-segmented into intermittent explosive disorder, pyromania, kleptomania, and others. Personality disorders include various traits such as emotional & impulsive, suspicious, anxious, and others. Dissociative disorder is sub-segmented into dissociative amnesia, dissociative identity disorder, depersonalization- derealization disorder, and others. Somatic symptom disorder somatization disorder, conversion disorder, hypochondriasis, factitious disorder, body dysmorphic disorder, and others. Factitious disorder is further sub-segmented into factitious disorder with mostly psychological symptoms, factitious disorder with mostly physical symptoms, factitious disorder with both psychological and physical symptoms, and others.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
